with us
together we’re making a difference

News Releases

Jul 11, 2022 |

Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

Jul 08, 2022 |

Annexon Announces $130 Million Private Placement Financing

Jun 07, 2022 |

Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

Jun 02, 2022 |

Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

Jun 01, 2022 |

Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings

May 09, 2022 |

Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results

May 05, 2022 |

Annexon Biosciences to Participate in Upcoming May Investor Conferences

Apr 07, 2022 |

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Apr 04, 2022 |

Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference

Mar 03, 2022 |

Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
Displaying 1 - 10 of 15
News Resources
Print
IR Contact
RSS Feeds
Email Alerts
Contact Us

info@annexonbio.com
650.822.5500

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

Annexon Biosciences

1400 Sierra Point Parkway,
Building C, 2nd Floor
Brisbane, CA 94005

© 2022 Annexon Inc. All rights reserved.